President Signs Changes To Trademark Dilution Law
Client Alert | 1 min read | 10.12.06
President Bush signs the Trademark Dilution Revision Act of 2006 (“Act”), amending the Lanham Act in response to the Supreme Court's decision in Moseley v. V Secret Catalogue, Inc ., 537 U.S. 418 (2003), which held that a dilution plaintiff must show actual dilution of its mark.
The Act lowers the standard set out in Moseley and provides that a plaintiff only needs to show a likelihood of dilution to sustain a claim. It specifically provides for relief from both dilution by blurring and dilution by tarnishment.
The new law also addresses a conflict among the Circuit Courts regarding whether a mark can be famous among a defined segment of the population, known as “niche market fame.” “Niche market” fame in a limited market appears to be disqualified by the Act's language that “a mark is famous if it is widely recognized by the general consuming public of the United States as a designation of source of the goods or services of the mark's owner.”
Insights
Client Alert | 3 min read | 05.26.26
On May 13, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment of no infringement in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 24-1641. The decision offers important guidance for patent holders and generic manufacturers on the role of industry standards in interpreting scientific terminology during claim construction, prosecution history estoppel, and the disclosure-dedication rule.
Client Alert | 5 min read | 05.26.26
Client Alert | 7 min read | 05.21.26
A New Playbook for M&A in the EU: The European Commission's Draft Merger Guidelines - 10 Key Changes
Client Alert | 3 min read | 05.21.26
Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases
